Drug maker Valeant is trying to either end or rework its deal with Walgreens after cutting its profit forecast and saying that its agreement with the retailer is partly to blame.
Valeant’s (NYSE: VRX) main issue, the Financial Times explained, is that Walgreens (NASDAQ: WBA) fills prescriptions for customers without prior assurance that insurers will pay for those drugs. That’s a problem because Valeant’s current deal with Walgreens calls for Walgreens to be paid for drugs it dispenses even…
Drug maker Valeant is trying to either end or rework its deal with Walgreens after cutting its profit forecast and saying that its agreement with the retailer is partly to blame.
Valeant’s (NYSE: VRX) main issue, the Financial Times explained, is that Walgreens (NASDAQ: WBA) fills prescriptions for customers without prior assurance that insurers will pay for those drugs. That’s a problem because Valeant’s current deal with Walgreens calls for Walgreens to be paid for drugs it dispenses even…